Outcome Evaluation of Minority AIDS Initiative Programs in the New York EMA
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 5,100
- 试验地点
- 23
- 主要终点
- Functional Health Status (ACTG SF-21): at 3, 6, and 12 mos.
研究概览
简要总结
This outcome evaluation effort provides the opportunity to learn what programmatic approaches effectively address two of the most difficult hurdles in HIV health services delivery: (1) getting people who would benefit from health care to use it and (2) getting people who do use health care to do so more consistently and effectively. The New York HIV Planning Council (through MHRA) has funded 23 agencies to achieve these objectives for people of color with HIV disease.
详细描述
All clients are assessed upon entry into the program, have their service utilization tracked, and then are reassessed at three, six, and twelve months following program entry.
The main client-level data elements collected during baseline and follow-up interviews are the following:
- Biological markers (including HIV status, viral load, t-cell count)
- Demographic characteristics
- Adherence to treatment
- Barriers to care
- Social support
- Substance use and treatment
- Functional health status
Functional Health Status is used in this evaluation as the primary measure of final client "outcomes." The Functional Health Status items we use are from the ACTG SF-21 (a modified version of the Medical Outcomes Study instrument).
The overall evaluation objectives are to:
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 0 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •HIV-positive
- •Not in HIV care, or difficulty being maintained in HIV care
- •HIV-negative but at high risk of HIV infection
排除标准
- •HIV-negative and not at high risk of HIV infection
结局指标
主要结局
Functional Health Status (ACTG SF-21): at 3, 6, and 12 mos.
次要结局
- Housing stability: at 3, 6, and 12 months
- Substance use: at 3, 6, and 12 months
- Whether receiving HIV primary care: at 3, 6, and 12 months
- Whether on HIV meds: at 3, 6, and 12 months